#11
|
||||
|
||||
United States Food and Drug Administration (FDA) Cardiovascular and Renal Advisory Committee voted against a labelling indication for aspirin that was based on assessment of absolute risk of coronary heart disease, for which age is the major determinant. The FDA Committee called for a trial to provide the evidence for aspirin use in individuals at moderate cardiovascular risk.
__________________
Искренне, Вадим Валерьевич. |